T-group (topology)
633.1.1 Bromodomain
Ligands and drugs
4,615
Member domains
3,153
with ligand contacts (≤ 4 Å)
68.3% of members
3,141
with DrugDomain annotations
68.1% of members
943
with a DrugBank compound
20.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 633.1.1 belongs to X-group 633 Bromodomain-like, which binds 10.0 ligand superclasses per 20 proteins, broader than 94% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB16107 | R78 | 4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide | 24 |
| DB12521 | MB3 | 1-methylpyrrolidin-2-one | 11 |
| DB19199 | HWV | N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | 8 |
| DB00316 | TYL | N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) | 7 |
| DB03345 | BME | BETA-MERCAPTOETHANOL | 6 |
| DB04447 | DTT | 2,3-DIHYDROXY-1,4-DITHIOBUTANE | 6 |
| DB04580 | 12Q | 1-METHYLQUINOLIN-2(1H)-ONE | 6 |
| DB12000 | 1K0 | 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquinazolin-4(3H)-one | 6 |
| DB16239 | EAM | 2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide | 6 |
| DB12062 | IBI | N-{trans-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-4-{[(7R)-7-ethyl-5-methyl-8-(1-methylethyl)-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxybenzamide | 5 |
| DB00277 | TEP | THEOPHYLLINE | 4 |
| DB00683 | 08J | 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine | 4 |
| DB01412 | 37T | THEOBROMINE | 4 |
| DB02676 | B3P | 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL | 4 |
| DB09273 | 7UH | Doxofylline | 4 |
| DB12500 | 2TA | N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide | 4 |
| DB00936 | SAL | 2-HYDROXYBENZOIC ACID | 3 |
| DB01394 | LOC | N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[d]heptalen-7-yl]ethanamide | 3 |
| DB00787 | AC2 | 9-HYROXYETHOXYMETHYLGUANINE | 2 |
| DB02210 | HEZ | HEXANE-1,6-DIOL | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAmetal | SODIUM ION | 652 |
| ZNmetal | ZINC ION | 159 |
| CL | CHLORIDE ION | 106 |
| CAmetal | CALCIUM ION | 24 |
| R78 | 4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide | 24 |
| BMF | Bromosporine | 22 |
| UNX | UNKNOWN ATOM OR ION | 19 |
| Kmetal | POTASSIUM ION | 17 |
| VYJ | 11-cyclopentyl-2-({2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]phenyl}amino)-5-methyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one | 14 |
| IOD | IODIDE ION | 13 |
| NImetal | NICKEL (II) ION | 13 |
| 2LO | 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole | 12 |
| 73B | 4-[(2S,4R)-1-acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl]benzoic acid | 12 |
| 8L6 | Physachenolide C | 12 |
| MB3 | 1-methylpyrrolidin-2-one | 11 |
| N6I | (3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one | 10 |
| MGmetal | MAGNESIUM ION | 9 |
| SCN | THIOCYANATE ION | 9 |
| YF2 | N-{1-[1,1-di(pyridin-2-yl)ethyl]-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl}ethanesulfonamide | 9 |
| 2XD | (2E)-1-(2-hydroxyphenyl)-3-(2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)prop-2-en-1-one | 8 |